211247-50-6

Basic information

• Product Name: 1-(4-AMINOPHENYL)-3-PIPERIDINEMETHANOL
• Synonyms: 1-(4-AMINOPHENYL)-3-PIPERIDINEMETHANOL
• CAS NO: 211247-50-6
• Molecular Formula: C₁₂H₁₈N₂O
• Molecular Weight: 206.287
• Mol File: 211247-50-6.mol
• Article Data: 6

Chemical Properties

• Appearance: /
• Storage Temp.: Keep in dark place,Sealed in dry,Room Temperature
• CAS DataBase Reference: 1-(4-AMINOPHENYL)-3-PIPERIDINEMETHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(4-AMINOPHENYL)-3-PIPERIDINEMETHANOL(211247-50-6)
• EPA Substance Registry System: 1-(4-AMINOPHENYL)-3-PIPERIDINEMETHANOL(211247-50-6)

Safety Data

• Hazardous Substances Data: 211247-50-6(Hazardous Substances Data)

Usage

General Description

1-(4-Aminophenyl)-3-piperidinemethanol is a chemical compound with potential pharmacological properties. It is a compound that consists of a piperidine ring with a hydroxyethyl group and an aminophenyl group attached. 1-(4-AMINOPHENYL)-3-PIPERIDINEMETHANOL has shown potential as a pharmaceutical intermediate and can be used in the synthesis of various pharmaceutical drugs. It has also been studied for its potential therapeutic effects, including its role as an antipsychotic and analgesic agent. Additionally, this compound has been investigated for its potential use in the treatment of various neurological disorders. Overall, 1-(4-Aminophenyl)-3-piperidinemethanol is a versatile compound with potential pharmaceutical applications.

Upstream product

• 4606-65-9 3-(hydroxymethy)piperidine 
• 350-46-9 4-Fluoronitrobenzene 
• 166438-83-1 (1-(4-nitrophenyl)piperidin-3-yl)methanol 

Relevant articles and documents

COMPOUNDS FOR REGULATING FAK AND/OR SRC PATHWAYS

The present application provides novel optionally substituted fused pyridine and pyrimidine bicyclic compounds and pharmaceutically acceptable salts thereof. Also provided are methods for preparing these compounds. These compounds are useful in co-regulating FAK and/or Src activity by administering a therapeutically effective amount of one or more of the compounds to a subject. By doing so, these compounds are effective in treating conditions associated with the dysregulation of the FAK and/or Src pathway. Advantageously, these compounds perform as dual FAK and/or Src inhibitors. A variety of conditions can be treated using these compounds and include diseases which are characterized by inflammation or abnormal cellular proliferation. In one embodiment, the disease is cancer.

MICROANGIOPATHY TREATMENT AND PREVENTION

The present invention relates to the use of selective factor Xa inhibitors, in particular of oxazolidinones of the formula (I) for the treatment and/or prophylaxis of microangiopathies and also their use for the production of medicaments for the treatment and/or prophylaxis of microangiopathies.

Pyridopyrimidinone derivatives for treatment of neurodegenerative disease

This invention provides pyridopyrimidines and 4-aminopyrimidines that are useful for treating cell proliferatives disorders, such as cancer and restenosis. We have now discovered a group of 7,8-dihydro-2 (amino and thio)pyrido[2,3-d]pyrimidines and 2,4-di